A disciplined view of the company, for qualified investors.
This page summarizes PathFree's investment thesis, product, development stage, evidence roadmap, market context, IP posture, leadership, and milestones. It is a public overview only. Terms, projections, and forward-looking financial content are shared through Investor Materials with qualified parties.
Content dated 2026-07-13
A defensible category, built responsibly.
Four pillars that describe the opportunity without overstating it.
The clinical problem
In-hospital cardiac arrest is time-critical, team-based, and under-supported by purpose-built coordination and documentation tools. Outcomes depend as much on team coordination as on individual clinical action.
The product / platform
AiMediQ™ is an AI-enabled Code Blue support system powered by the datasyteAI™ platform. Clinician-in-the-loop by design; scoped to coordination, calculation support, and structured documentation.
Development stage
Pre-commercial. Multidisciplinary team assembled; product scope, architecture, and governance model documented. Regulatory strategy and clinical evaluation plan in development.
Why now
Institutional appetite for governed clinical-AI is growing, and coordination-oriented decision support is a defensible category adjacent to — not competing with — clinical judgment.
Staged evidence, honestly labeled.
Full evidence detail lives on the Evidence page. This is a summary for investor readers.
| Stage | State | Notes |
|---|---|---|
| Technical validation | In Progress | Internal platform behavior, versioning, and change-control conformance. |
| Structured simulation | Planned | High-fidelity simulation with qualified teams; workflow and documentation endpoints. |
| Institutional pilots | Planned | Pilot sites and evaluation partners to be announced only after institutional and regulatory review. |
| Peer-reviewed publication | Planned | Endpoints and design confirmed with clinical advisors and prospective partners. |
Category, buyers, and sizing.
Where we play and who buys — with sizing gated on an approved, dated source.
Category
Clinical-AI decision support for in-hospital resuscitation coordination — a defined, high-acuity workflow with existing team structure and documentation practice.
Buyers
Institutional buyers: clinical leadership, resuscitation committees, IT, security, and compliance stakeholders. Not a consumer product.
Market sizing
PathFree operates at the intersection of AI-enabled clinical decision support and AI-assisted clinical documentation. Third-party category estimates are shown below as separate, non-additive indicators — not as PathFree revenue projections or expected market share. Source-controlled as of July 14, 2026.
Market categories overlap and are not additive. Third-party estimates depend on market definitions, assumptions, and forecasting methodologies. Figures do not represent PathFree revenue projections or expected market share.
A conservative view of IP.
We do not infer clinical or regulatory conclusions from IP status.
Trademarks
PathFree Technologies, AiMediQ™, and datasyteAI™ are used to identify our company, product, and platform. Trademark applications are pending in the U.S.; registration status varies by jurisdiction.AiMediQ™ on Justia•datasyteAI™ on Justia
Patents
Patent activity is treated as forward-looking. A patent filing or grant does not, on its own, establish clinical efficacy or regulatory clearance. U.S. patent application 20250205006, "Intelligent Code Cart," filed December 20, 2024 and published June 26, 2025, is assigned to PathFree Technologies Corporation.View patent filings on Justia
Confidential know-how
Architecture, protocol configuration approach, and evaluation design are treated as confidential and are shared under NDA with qualified parties.
The people executing the plan.
A short list for investor context. Full profiles and advisors are on the Company page.
- Dr. Perry M. Brunette—CEO & Founder
- Lianna Zhang—Co-Founder
- Darren Saravis—CTO
- Dr. Lia DiBello—CSO
- Kerri Eis, RN, BSN, CLNC—Clinical AdvisorAdvisor
- Jeenchen (Robert) Chen, MD, MPH—CMO
Historical accomplishments and forward-looking plans, kept separate.
We do not blend done and planned. Every forward-looking item is dated only when approved.
- June 2021Completed
Company formation
PathFree Technologies established
Focus set on AI-enabled emergency cardiovascular response.
- January 2023Completed
Team
Multidisciplinary team assembled
Clinical, regulatory, technical, financial, and operating leadership in place.
- July 2023Completed
Platform
datasyteAI™ platform framing
Intelligence and orchestration layer defined.
- August 2024Completed
Product
AiMediQ™ design articulated
Product scope, modules, and clinician-in-the-loop model documented.
- July 2026Completed
Governance
Claims register and evidence discipline
Internal claims register and public evidence page adopted.
- [APPROVED DATE]Planned
Evaluation
Structured clinical evaluation plan finalized
Prepared with clinical advisors and prospective pilot partners.
- [APPROVED DATE]Planned
Regulatory
Regulatory strategy execution
Regulatory pathway and jurisdictions to be disclosed only when approved.
- [APPROVED DATE]Planned
Deployment
Institutional pilots
Pilot sites and evaluation partners will be announced only after institutional and regulatory review.
Approved public updates.
Only approved public news items appear here. Investor-only updates are shared through the materials request.
PathFree Technologies Unveils Redesigned Website as StartEngine Preparation Advances
PathFree Technologies has launched a redesigned corporate website offering a clearer, more transparent presentation of AiMediQ™ powered by datasyteAI™, the company's development strategy and its preparation for a potential StartEngine campaign.
Request Investor Materials.
Access to the data room and Investor Materials is provided through a structured request. Sign in is required, and document-level access is granted individually. Terms and forward-looking financial content are shared only with qualified parties under appropriate confidentiality.